| Recruiting | Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dy NCT07388966 | SYSNAV | — |
| Not Yet Recruiting | A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondropl NCT07441876 | BioMarin Pharmaceutical | Phase 2 / Phase 3 |
| Not Yet Recruiting | A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondropla NCT07297875 | Abbisko Therapeutics Co, Ltd | Phase 1 / Phase 2 |
| Recruiting | Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) NCT07169279 | QED Therapeutics, a BridgeBio company | Phase 2 |
| Recruiting | A Study in Children With Achondroplasia NCT07301463 | Abbisko Therapeutics Co, Ltd | — |
| Recruiting | A Study of TYRA-300 in Children With Achondroplasia: BEACH301 NCT06842355 | Tyra Biosciences, Inc | Phase 2 |
| Recruiting | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With A NCT06732895 | Ascendis Pharma A/S | Phase 2 |
| Recruiting | Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study） NCT06926491 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With L NCT06433557 | Ascendis Pharma Growth Disorders A/S | Phase 2 |
| Recruiting | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Yea NCT06079398 | Ascendis Pharma A/S | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia NCT06164951 | QED Therapeutics, a BridgeBio company | Phase 3 |
| Enrolling By Invitation | A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With NCT05929807 | Ascendis Pharma Growth Disorders A/S | Phase 2 / Phase 3 |
| Terminated | Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants NCT05813314 | BioMarin Pharmaceutical | Phase 1 |
| Completed | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achond NCT05598320 | Ascendis Pharma Growth Disorders A/S | Phase 2 / Phase 3 |
| Recruiting | VIrtual STudy in Achondroplasia for the US (VISTA) NCT06168201 | BioMarin Pharmaceutical | — |
| Completed | A Study to Learn About Recifercept in Patients With Achondroplasia NCT05659719 | Pfizer | — |
| Unknown | A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasi NCT05353192 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 4 |
| Unknown | Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Ch NCT05603936 | Universitätsklinikum Hamburg-Eppendorf | — |
| Unknown | A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of Tr NCT05246033 | Ascendis Pharma A/S | Phase 2 |
| Terminated | Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondro NCT05116046 | Pfizer | Phase 2 |
| Enrolling By Invitation | Extension Study of Infigratinib in Children With Achondroplasia (ACH) NCT05145010 | QED Therapeutics, a BridgeBio company | Phase 2 |
| Recruiting | Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy) NCT05328050 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | — |
| Terminated | A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia NCT04638153 | Pfizer | Phase 2 |
| Active Not Recruiting | A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia NCT04554940 | BioMarin Pharmaceutical | Phase 2 |
| Completed | A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once We NCT04085523 | Ascendis Pharma A/S | Phase 2 |
| Completed | Study of Infigratinib in Children With Achondroplasia NCT04265651 | QED Therapeutics, a BridgeBio company | Phase 2 |
| Unknown | Radiological Analysis on Patients With Achondroplasia Disorder NCT04184817 | Hospices Civils de Lyon | — |
| Completed | Prospective Clinical Assessment Study in Children With Achondroplasia (ACH) NCT04035811 | QED Therapeutics, a BridgeBio company | — |
| Completed | A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia NCT03875534 | Ascendis Pharma A/S | — |
| Active Not Recruiting | An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia NCT03989947 | BioMarin Pharmaceutical | Phase 2 |
| Completed | Lifetime Impact Study for Achondroplasia NCT03872531 | BioMarin Pharmaceutical | — |
| Terminated | Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia. NCT03794609 | Pfizer | — |
| Completed | A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondropla NCT03583697 | BioMarin Pharmaceutical | Phase 2 |
| Completed | Lifetime Impact of Achondroplasia Study in Europe-LIAISE NCT03449368 | BioMarin Pharmaceutical | — |
| Active Not Recruiting | An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia NCT03424018 | BioMarin Pharmaceutical | Phase 3 |
| Completed | The Norwegian Adult Achondroplasia Study NCT03780153 | Sunnaas Rehabilitation Hospital | — |
| Completed | A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia NCT03197766 | BioMarin Pharmaceutical | Phase 3 |
| Recruiting | Achondroplasia Natural History Multicenter Clinical Study NCT02597881 | Johns Hopkins University | — |
| Active Not Recruiting | A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH NCT02724228 | BioMarin Pharmaceutical | Phase 2 |
| Completed | A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia NCT02055157 | BioMarin Pharmaceutical | Phase 2 |
| Completed | A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin NCT01435629 | Novo Nordisk A/S | — |
| Completed | A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia NCT01603095 | BioMarin Pharmaceutical | — |
| Completed | A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers NCT01590446 | BioMarin Pharmaceutical | Phase 1 |
| Completed | C-Type Natriuretic Peptide and Achondroplasia NCT01541306 | Nemours Children's Clinic | — |
| Completed | Special Survey for Long Term Application NCT01516229 | Novo Nordisk A/S | — |
| Completed | Issues Surrounding Prenatal Genetic Testing for Achondroplasia NCT00001536 | National Human Genome Research Institute (NHGRI) | — |